Metabolic profile of a continuous versus a cyclic low-dose combined oral contraceptive after one year of use

References

• Machado RB, Fabrini P, Cruz AM, et al. Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 microg) and gestodene (75 microg). Contraception 2004;70:365–70.
   PubMed Web of Science ®Google Scholar
• Machado RB, De Melo NR, Maia H, Jr., et al. Effect of a continuous regimen of contraceptive combination of ethinylestradiol and drospirenone on lipid, carbohydrate and coagulation profiles. Contraception 2010;81:102–6.
   PubMed Web of Science ®Google Scholar
• Teichmann A, Apter D, Emerich J, et al. Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: Efficacy, safety and bleeding in a randomized, open-label trial. Contraception 2009;80:504–11.
   PubMed Web of Science ®Google Scholar
• Hanley AJ, Williams K, Stern MP, et al. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: The San Antonio Heart Study. Diabetes Care 2002;25:1177–84.
   PubMed Web of Science ®Google Scholar
• Kemmeren JM, Algra A, Grobbee DE. Effect of second and third generation oral contraceptives on lipid metabolism in the absence or presence of the factor V Leiden mutation. J Intern Med 2001;250:441–8.
   PubMed Web of Science ®Google Scholar
• Burkman RT. Lipid metabolism effects with desogestrel-containing oral contraceptives. Am J Obstet Gynecol 1993;168:1033–40.
   PubMed Web of Science ®Google Scholar
• Crook D, Godsland I. Safety evaluation of modern oral contraceptives. Effects on lipoprotein and carbohydrate metabolism. Contraception 1998;57:189–201.
   PubMed Web of Science ®Google Scholar
• Endrikat J, Klipping C, Cronin M, et al. An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. Contraception 2002;65:215–21.
   PubMed Web of Science ®Google Scholar
• Scharnagl H, Petersen G, Nauck M, et al. Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 microg or 30 microg) and levonorgestrel (100 microg or 150 microg) on lipoprotein metabolism. Contraception 2004;69:105–13.
   PubMed Web of Science ®Google Scholar
• Young RL, DelConte A. Effects of low-dose monophasic levonorgestrel with ethinyl estradiol preparation on serum lipid levels: A twenty-four-month clinical trial. Am J Obstet Gynecol 1999;181:S59–S62.
   Google Scholar
• Skouby SO, Endrikat J, Dusterberg B, et al. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 μg ethinyl estradiol combined with 100 μg levonorgestrel. Contraception 2005;71:111–7.
   PubMed Web of Science ®Google Scholar
• Kiran G, Kiran H, Ekerbicer HC. Serum lipid and lipoprotein changes induced by preparations containing low-dose ethinyl estradiol plus levonorgestrel. Aust NZ J Obstet Gynecol 2003;43:145–7.
   PubMed Web of Science ®Google Scholar
• Lamarche B, Moorjani S, Cantin B, et al. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 1997;17:1098–105.
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486–97.
   PubMed Web of Science ®Google Scholar
• Odlind V, Milsom I, Persson I, et al. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand 2002;81:482–90.
   PubMed Web of Science ®Google Scholar
• Oral Contraceptive and Hemostasis Study Group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. Contraception 2003;67:173–85.
   PubMed Web of Science ®Google Scholar
• Chavez A, DelConte A. A comparison of cycle control with monophasic levonorgestrel/ethinylestradiol 100 ug/20 ug versus triphasic norethindrone/ethinylestradiol 500-750-1000 ug/35 ug: a multicenter, randomized, open-label study. Eur J Contracept Reprod Health Care 1999;4:75–83.
   PubMedGoogle Scholar
• Archer DF, Maheux R, DelConte A, et al. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 μg levonorgestrel and 20 μg ethinyl estradiol (Alesse). Am J Obstet Gynecol 1999;181:S39–S44.
   PubMed Web of Science ®Google Scholar